Genetic screening for gynecological cancer: where are we heading?
207 - 220
MetadataShow full item record
The landscape of cancer genetics in gynecological oncology is rapidly changing. The traditional family history-based approach has limitations and misses >50% mutation carriers. This is now being replaced by population-based approaches. The need for changing the clinical paradigm from family history-based to population-based BRCA1/BRCA2 testing in Ashkenazi Jews is supported by data that demonstrate population-based BRCA1/BRCA2 testing does not cause psychological harm and is cost effective. This article covers various genetic testing strategies for gynecological cancers, including population-based approaches, panel and direct-to-consumer testing as well as the need for innovative approaches to genetic counseling. Advances in genetic testing technology and computational analytics have facilitated an integrated systems medicine approach, providing increasing potential for population-based genetic testing, risk stratification, and cancer prevention. Genomic information along-with biological/computational tools will be used to deliver predictive, preventive, personalized and participatory (P4) and precision medicine in the future.
AuthorsManchanda, R; Jacobs, I
Showing items related by title, author, creator and subject.
WS57: Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research (14-Oct-2014) History of Twentieth Century Medicine Group; History of Modern Biomedicine Research Group; Farnetti T (2017-06-06)Selection of photos taken at the Witness Seminar “Medical Genetics: Development of Ethical Dimensions in Clinical Practice and Research" held by the History of Modern Biomedicine Research Group, 14-Oct-2014. Participants: ...
History of Twentieth Century Medicine Group; History of Modern Biomedicine Research Group (2017-05-31)Selection of photos taken at the Witness Seminar “Clinical Genetics in Britain: Origins and development” held by the History of Twentieth Century Medicine Group, 23-Sep-2008. Participants: Ms Chris Barnes, Dr Caroline ...
A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. Jervis, S; Song, H; Lee, A; Dicks, E; Harrington, P; Baynes, C; Manchanda, R; Easton, DF; Jacobs, I; Pharoah, PPD (2015-07)BACKGROUND: Although BRCA1 and BRCA2 mutations account for only ∼27% of the familial aggregation of ovarian cancer (OvC), no OvC risk prediction model currently exists that considers the effects of BRCA1, BRCA2 and other ...